Hoechst Aktiengesellschaft

Hans-Peter Schubert

John J Grome

Karl Rudolphi

Ulrich Gebert

Hildegard Nimmesgern

Barbara Kittner

Ralf Kolvenbach

Viera Danielisova

Ernst J Schneider

The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

Combination preparation for use in dementia

The use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine or of physiologically tolerated salts of this compound for the preparation of pharmaceuticals for the prophylaxis and treatment of nerve damage after interruption of the blood circulation is disclosed.

Use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine in vascular surgery

The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I ##STR1## and of their physiologically tolerable salts, in which R.sup.1 is oxoalkyl, hydroxyalkyl or alkyl, R.sup.2 is hydrogen or alkyl and R.sup.3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.

Xanthine derivatives for the treatment of secondary nerve cell damage

Growing community of inventors

Apfeldorf, Germany

Hans-Peter Schubert